Why the study?
Does ticlopidine improve walking distance and prevent cardiovascular events in patients with chronic intermittent claudication?
Population
169 patients with chronic intermittent claudication due to obstructive peripheral vascular disease
Comparison
Ticlopidine 250 mg twice daily vs Placebo twice daily
Design
RCT, Randomized into two parallel groups, Double-blind
Follow-up
6 months
Authors
Loading...
Supports ticlopidine use in intermittent claudication; extends antiplatelet evidence to peripheral artery disease.
Does ticlopidine improve walking distance and prevent cardiovascular events in patients with chronic intermittent claudication?
Ticlopidine improves walking distance and reduces cardiovascular events in patients with intermittent claudication.
Arcan et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: